PNR
65
3
KIM
60
3
ETN
67
-2
HPE
73
4
PRU
65
11
LOW
45
2
NOV
55
2
LNC
63
-2
CF
63
-2
NUE
64
2
AA
72
5
NSC
53
2
GOOG
65
2
VTR
38
4
MTCH
62
3
REGN
46
2
ADP
68
-4
C
71
-6
MMM
56
4
CFG
95
2
PNR
65
3
KIM
60
3
ETN
67
-2
HPE
73
4
PRU
65
11
LOW
45
2
NOV
55
2
LNC
63
-2
CF
63
-2
NUE
64
2
AA
72
5
NSC
53
2
GOOG
65
2
VTR
38
4
MTCH
62
3
REGN
46
2
ADP
68
-4
C
71
-6
MMM
56
4
CFG
95
2
Financhill
Back

Y-mAbs Therapeutics 10K Form

Sell
22

YMAB
Y-mAbs Therapeutics

Last Price:
$4.35
Seasonality Move:
-4.07%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive YMAB News And Ratings

See the #1 stock for the next 7 days that we like better than YMAB

YMAB Financial Statistics

Sales & Book Value

Annual Sales: $87.7M
Cash Flow: $-7M
Price / Cash Flow: 0
Annual Sales: $1.98
Price / Book: 2.29

Profitability

EPS (TTM): -0.64000
Net Income (TTM): $-28.2M
Gross Margin: $72.4M
Return on Equity: -30.14%
Return on Assets: -22.74%

Y-mAbs Therapeutics Earnings Forecast

Key Y-mAbs Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 6 years for YMAB is 82.61%.
  • The Selling, General & Administrative Expenses for YMAB have been equal to 62.32% of Gross Profit Margin.
  • The Research & Development expenses have been 55.87% of Revenue.
  • The Net Earning history of YMAB is -33.83% of Total Revenues.
  • Per Share Earnings over the last 9 years have been positive in 2 years.

Y-mAbs Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: YMAB
CUSIP: 984241
Website: ymabs.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.77
Quick Ratio: 4.12

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

YMAB Technical Analysis vs Fundamental Analysis

Sell
22
Y-mAbs Therapeutics (YMAB) is a Sell

Is Y-mAbs Therapeutics a Buy or a Sell?